ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary …
ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review c